Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY. Arrillaga-Romany I, et al. Neuro Oncol. 2020 Jan 11;22(1):94-102. doi: 10.1093/neuonc/noz164. Neuro Oncol. 2020. PMID: 31702782 Free PMC article. Clinical Trial.
Neurologic complications of cancer drug therapies.
Lee EQ, Arrillaga-Romany IC, Wen PY. Lee EQ, et al. Continuum (Minneap Minn). 2012 Apr;18(2):355-65. doi: 10.1212/01.CON.0000413663.42798.64. Continuum (Minneap Minn). 2012. PMID: 22810132 Review.
Current status of antiangiogenic therapies for glioblastomas.
Arrillaga-Romany I, Reardon DA, Wen PY. Arrillaga-Romany I, et al. Expert Opin Investig Drugs. 2014 Feb;23(2):199-210. doi: 10.1517/13543784.2014.856880. Epub 2013 Dec 10. Expert Opin Investig Drugs. 2014. PMID: 24320142 Review.
Antiangiogenic therapies for glioblastoma.
Arrillaga-Romany I, Norden AD. Arrillaga-Romany I, et al. CNS Oncol. 2014;3(5):349-58. doi: 10.2217/cns.14.31. CNS Oncol. 2014. PMID: 25363007 Free PMC article. Review.
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.
Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Ellingson BM, et al. Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053. Neuro Oncol. 2018. PMID: 29660006 Free PMC article. Clinical Trial.
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Prabhu VV, et al. Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17. Clin Cancer Res. 2019. PMID: 30559168 Free PMC article.
Accelerated progression of IDH mutant glioma after first recurrence.
Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Miller JJ, et al. Neuro Oncol. 2019 May 6;21(5):669-677. doi: 10.1093/neuonc/noz016. Neuro Oncol. 2019. PMID: 30668823 Free PMC article.
Performance of a Hospital Pathway for Patients With a New Single Brain Mass.
Arrillaga-Romany I, Curry WT Jr, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT. Arrillaga-Romany I, et al. J Oncol Pract. 2019 Mar;15(3):e211-e218. doi: 10.1200/JOP.17.00098. Epub 2019 Jan 25. J Oncol Pract. 2019. PMID: 30681891
50 results